{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:50Z","timestamp":1790755670800,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.autrev.2018.09.008","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:14:07Z","timestamp":1547198047000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy"],"prefix":"10.1016","volume":"18","author":[{"given":"C\u00e9line","family":"Anquetil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Wesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.09.008_bb0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.autrev.2018.09.008_bb0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2018.09.008_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.nmd.2014.01.002","article-title":"Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients","volume":"24","author":"Wang","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2018.09.008_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.09.008_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0030","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","article-title":"Human autoantibodies reactive with the signal-recognition particle","volume":"83","author":"Reeves","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2018.09.008_bb0035","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nature02342","article-title":"Structure of the signal recognition particle interacting with the elongation-arrested ribosome","volume":"427","author":"Halic","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2018.09.008_bb0040","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1093\/emboj\/cdg337","article-title":"New EMBO member's review","volume":"22","author":"Nagai","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.autrev.2018.09.008_bb0045","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar1895","article-title":"Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages","volume":"8","author":"R\u00f6misch","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2018.09.008_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2018.09.008_bb0055","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti\u2013signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.09.008_bb0060","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2018.09.008_bb0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/gb-2004-5-11-248","article-title":"The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases","volume":"5","author":"Friesen","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0070","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/emboj\/19.5.819","article-title":"Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis","volume":"19","author":"Istvan","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.autrev.2018.09.008_bb0075","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.09.008_bb0080","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2015.09.065","article-title":"Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy","volume":"466","author":"Osaki","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2018.09.008_bb0085","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2018.09.008_bb0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti\u2013signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.09.008_bb0095","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2013.08.008","article-title":"Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM)","volume":"264","author":"Rojana-udomsart","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0105","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3346\/jkms.2009.24.6.1015","article-title":"Differential immunohistological features of inflammatory myopathies and dysferlinopathy","volume":"24","author":"Choi","year":"2009","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.autrev.2018.09.008_bb0110","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.autrev.2017.03.001","article-title":"Animal models in idiopathic inflammatory myopathies: how to overcome a translational roadblock?","volume":"16","author":"Afzali","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.008_bb0115","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","author":"Bergua","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.09.008_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop::clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, the Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2018.09.008_bb0125","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2018.09.008_bb0130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12026-016-8867-x","article-title":"Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure","volume":"65","author":"Shovman","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2018.09.008_bb0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.60.2.116","article-title":"Autoantibody profiles in the sera of European patients with myositis","volume":"60","author":"Brouwer","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.09.008_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/PL00007850","article-title":"Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies","volume":"249","author":"Hengstman","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0145","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.008_bb0150","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/keu436","article-title":"Anti-signal recognition particle autoantibody ELISA validation and clinical associations","volume":"54","author":"Aggarwal","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2018.09.008_bb0155","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jneuroim.2014.07.006","article-title":"Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies","volume":"274","author":"Suzuki","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.autrev.2018.09.008_bb0165","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000124","article-title":"Myopathy with anti-HMGCR antibodies","volume":"2","author":"Alshehri","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.autrev.2018.09.008_bb0170","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jocn.2014.04.031","article-title":"Anti-synthetase syndrome associated with anti PL-12 and anti-signal recognition particle antibodies and a necrotizing auto-immune myositis","volume":"22","author":"Malkan","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.autrev.2018.09.008_bb0175","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10067-010-1394-6","article-title":"An unusual association: anti-Jo1 and anti-SRP antibodies in the serum of a patient with polymyositis","volume":"29","author":"Vincze","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2017.07.011","article-title":"Detection of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase by ELISA in a reference laboratory setting","volume":"472","author":"Jaskowski","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2018.09.008_bb0185","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/405956","article-title":"Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies","volume":"2014","author":"Musset","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2018.09.008_bb0190","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2016.09.005","article-title":"Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories","volume":"15","author":"Alvarado-Cardenas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.008_bb0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.autrev.2017.01.002","article-title":"Anti-HMGCR and anti-DFS70 antibodies immunofluorescence patterns","volume":"16","author":"Palterer","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.008_bb0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti\u20133-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2018.09.008_bb0205","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.008_bb0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CND.0000000000000115","article-title":"Chronic myopathy associated with anti-signal recognition particle antibodies can be misdiagnosed as facioscapulohumeral muscular dystrophy","volume":"17","author":"Ikeda","year":"2016","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2018.09.008_bb0215","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/TCRM.S162931","article-title":"Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure \u2013 narrative review of the literature\u2014case report","volume":"14","author":"Carvalho AA de S, da Silva VG, Zanoteli E, Feder D.","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.autrev.2018.09.008_bb0220","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/mus.25567","article-title":"Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase necrotizing myopathy masquerading as a muscular dystrophy in a child","volume":"56","author":"Mohassel","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2018.09.008_bb0225","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000172","article-title":"Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease","volume":"2","author":"Mammen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.autrev.2018.09.008_bb0230","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","article-title":"Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies","volume":"56","author":"Liang","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2018.09.008_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2018.09.008_bb0240","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2018.09.008_bb0245","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.09.008_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.09.008_bb0255","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.12659\/MSM.907380","article-title":"Immunopathological characterization of muscle biopsy samples from immune-mediated necrotizing myopathy patients","volume":"24","author":"Wang","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.autrev.2018.09.008_bb0260","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preu\u00dfe","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0265","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumdis-2016-210198","article-title":"Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity","volume":"76","author":"Pinal-Fernandez","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.09.008_bb0270","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.09.008_bb0275","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.09.008_bb0280","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.09.008_bb0285","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0290","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jnnp-2011-301339","article-title":"Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B","volume":"84","author":"Takahashi","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2018.09.008_bb0295","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4103\/0028-3886.40964","article-title":"Dysferlinopathy: a clinical and histopathological study of 28 patients from India","volume":"56","author":"Nalini","year":"2008","journal-title":"Neurol India"},{"key":"10.1016\/j.autrev.2018.09.008_bb0300","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.autrev.2017.07.016","article-title":"How I treat idiopathic patients with inflammatory myopathies in the clinical practice","volume":"16","author":"Cavagna","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.09.008_bb0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2014mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0310","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-017-0205-x","article-title":"Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature","volume":"15","author":"Binns","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.autrev.2018.09.008_bb0315","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.0303-17","article-title":"Development of necrotizing myopathy following interstitial lung disease with anti-signal recognition particle antibody","author":"Kusumoto","year":"2018","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.autrev.2018.09.008_bb0320","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/03009742.2015.1132761","article-title":"Anti-HMGCR antibody-associated necrotizing myopathy: diagnosis and treatment illustrated using a case report","volume":"45","author":"Giudizi","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0325","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody\u2013associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.autrev.2018.09.008_bb0330","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0335","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.09.008_bb0340","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","article-title":"Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)","volume":"16","author":"Arlet","year":"2006","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.autrev.2018.09.008_bb0345","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199205213262102","article-title":"Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis","volume":"326","author":"Miller","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.09.008_bb0350","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label","volume":"10","author":"Allenbach","year":"2015","journal-title":"Phase II Trial PloS One"},{"key":"10.1016\/j.autrev.2018.09.008_bb0355","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2018.09.008_bb0360","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.nmd.2016.06.211","article-title":"Rituximab for the treatment of anti-HMGCR necrotizing autoimmune myopathy","volume":"26","author":"Landon-Cardinal","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2018.09.008_bb0365","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.autrev.2018.09.008_bb0370","first-page":"2482","article-title":"Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production","volume":"194","author":"Chavele","year":"2015","journal-title":"J Immunol Baltim Md 1950"},{"key":"10.1016\/j.autrev.2018.09.008_bb0375","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.autrev.2018.09.008_bb0380","unstructured":"Tocilizumab in the treatment of refractory polymyositis and dermatomyositis - Full Text View - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02043548 (accessed June 28, 2018)."},{"key":"10.1016\/j.autrev.2018.09.008_bb0385","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/rheumatology\/ket251","article-title":"Successful treatment of refractory anti-signal recognition particle myopathy using abatacept","volume":"53","author":"Maeshima","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.09.008_bb0390","unstructured":"Trial to evaluate the efficacy and safety of abatacept in combination with standard therapy compared to standard therapy alone in improving disease activity in adults with active idiopathic inflammatory myopathy - Full Text View - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02971683 (accessed June 28, 2018)."},{"key":"10.1016\/j.autrev.2018.09.008_bb0395","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.09.008_bb0400","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11926-011-0169-7","article-title":"Malignancy in myositis","volume":"13","author":"Zahr","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2018.09.008_bb0405","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2018.09.008_bb0410","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:14:03Z","timestamp":1761599643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219300011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1568997219300011"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.09.008","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}